PlexBio Co., Ltd.
PlexBio Co., Ltd. develops and manufactures in vitro diagnostic reagents for molecular biology and immunology projects. It offers workflow navigation services; automated sample preparation kits; IntelliPlex platform that is designed for pCode technology with throughput sample-to-answer multiplexing assays; oncology assays, a portfolio for advanced molecular testing; and pCode coupling buffer sets… Read more
Market Cap & Net Worth: PlexBio Co., Ltd. (6572)
PlexBio Co., Ltd. (TWO:6572) has a market capitalization of $22.24 Million (NT$735.91 Million) as of March 19, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #29300 globally and #1823 in its home market, demonstrating a -11.25% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying PlexBio Co., Ltd.'s stock price NT$7.10 by its total outstanding shares 103649000 (103.65 Million).
PlexBio Co., Ltd. Market Cap History: 2026 to 2026
PlexBio Co., Ltd.'s market capitalization history from 2026 to 2026. Data shows growth from $22.24 Million to $22.24 Million (0.00% CAGR).
PlexBio Co., Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how PlexBio Co., Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 6572 by Market Capitalization
Companies near PlexBio Co., Ltd. in the global market cap rankings as of March 19, 2026.
Key companies related to PlexBio Co., Ltd. by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #78 globally with a market cap of $191.37 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #154 globally with a market cap of $121.03 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #168 globally with a market cap of $113.17 Billion USD.
- Boston Scientific Corp (NYSE:BSX): Ranked #185 globally with a market cap of $105.26 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #78 | Abbott Laboratories | NYSE:ABT | $191.37 Billion | $110.71 |
| #154 | Stryker Corporation | NYSE:SYK | $121.03 Billion | $349.11 |
| #168 | Medtronic PLC | NYSE:MDT | $113.17 Billion | $88.44 |
| #185 | Boston Scientific Corp | NYSE:BSX | $105.26 Billion | $71.20 |
PlexBio Co., Ltd. Historical Marketcap From 2026 to 2026
Between 2026 and today, PlexBio Co., Ltd.'s market cap moved from $22.24 Million to $ 22.24 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$22.24 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of PlexBio Co., Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $22.24 Million USD |
| MoneyControl | $22.24 Million USD |
| MarketWatch | $22.24 Million USD |
| marketcap.company | $22.24 Million USD |
| Reuters | $22.24 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.